Thrasos presents positive results of THR-184 compound for the treatment of acute kidney injury -
Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its composed of THR-184 lead development can effectively protect against the loss of renal function after acute ischemic injury in rats. Study results were presented at the 51 st European Renal Association -. Dialysis and Transplant European Association (ERA-EDTA) Congress to be held in Amsterdam, the Netherlands
THR-184 is a small exclusive peptide that acts on the BMP / Smad pathway. It is in development for the prevention and treatment of acute kidney injury (AKI). The results of a wide range of preclinical studies and two Phase 1 clinical trials in which THR-184 was safe and well tolerated, led to the design and initiation of a major clinical trial phase 2. This process is now underway in Canada and the United States and focuses on the prevention of AKI in patients undergoing cardiac surgery. THR-184 has been granted Fast Track designations for this indication by the US Food and Drug Administration (FDA) in February 2014.
In the studies presented today, THR-184 has been shown to reduce significantly the severity of AKI when administered in an animal model of acute renal ischemia. THR-184 was administered prior to the injury, after the injury, and both before and after the injury. The highest level of efficacy was observed when THR-184 was administered both before and after the injury.
"THR-184 has been studied extensively in my lab and demonstrated a strong and consistent performance in our animal model of AKI," said Bruce A. Molitoris, MD, professor of medicine in the Division of Nephrology at Indiana University. "I am excited to see the results of the large phase 2 study being conducted by Thrasos."
"This critical work so well executed by Dr. Molitoris and his team provided us the basis of our clinical program," said Richard Andrews, President and CEO of Thrasos. "Based data from these studies, we were able to progress our development program with safety and toxicology tests, two phase 1 studies, and more recently in an important clinical trial phase 2. our hope is that, following the ongoing test THR-184 can make a major contribution to the prevention and treatment of AKI. "
EmoticonEmoticon